Fresenius Kabi has entered into a partnership with US manufacturer Phlow Corp to establish a domestic, end-to-end supply chain for Epinephrine Injection, USP, a FDA designated essential medicine frequently at risk of shortage in the United States. Under the collaboration, Phlow will produce the US-based API, while Fresenius Kabi will manufacture the finished doses for hospitals and clinics. This initiative aims to advance the company’s local-for-local manufacturing strategy and support national efforts to strengthen pharmaceutical security. Pending regulatory approvals, epinephrine produced through this collaboration could be available to US hospitals next year.